JP2016510042A - ピリドピリミジンまたはピリミドピリミジン系化合物、その製造方法、薬剤組成物及びその用途 - Google Patents

ピリドピリミジンまたはピリミドピリミジン系化合物、その製造方法、薬剤組成物及びその用途 Download PDF

Info

Publication number
JP2016510042A
JP2016510042A JP2015560533A JP2015560533A JP2016510042A JP 2016510042 A JP2016510042 A JP 2016510042A JP 2015560533 A JP2015560533 A JP 2015560533A JP 2015560533 A JP2015560533 A JP 2015560533A JP 2016510042 A JP2016510042 A JP 2016510042A
Authority
JP
Japan
Prior art keywords
azabicyclo
oxa
octanoyl
pharmaceutically acceptable
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015560533A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510042A5 (enExample
Inventor
沈▲競▼康
余科
孟▲韜▼
▲馬▼▲蘭▼▲ぴん▼
▲薩▼斯科奥里耶
孟▲蘭▼芳
王▲シン▼
▲陳▼怡怡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fudan University
Original Assignee
Fudan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fudan University filed Critical Fudan University
Publication of JP2016510042A publication Critical patent/JP2016510042A/ja
Publication of JP2016510042A5 publication Critical patent/JP2016510042A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2015560533A 2013-03-04 2014-02-28 ピリドピリミジンまたはピリミドピリミジン系化合物、その製造方法、薬剤組成物及びその用途 Pending JP2016510042A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201310068888.8A CN103588792B (zh) 2013-03-04 2013-03-04 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途
CN201310068888.8 2013-03-04
PCT/CN2014/072678 WO2014135028A1 (zh) 2013-03-04 2014-02-28 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途

Publications (2)

Publication Number Publication Date
JP2016510042A true JP2016510042A (ja) 2016-04-04
JP2016510042A5 JP2016510042A5 (enExample) 2016-09-29

Family

ID=50079144

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015560533A Pending JP2016510042A (ja) 2013-03-04 2014-02-28 ピリドピリミジンまたはピリミドピリミジン系化合物、その製造方法、薬剤組成物及びその用途

Country Status (11)

Country Link
US (1) US9796732B2 (enExample)
EP (1) EP2966079B1 (enExample)
JP (1) JP2016510042A (enExample)
CN (1) CN103588792B (enExample)
AU (1) AU2014225155B2 (enExample)
CA (1) CA2903072C (enExample)
DE (1) DE14760712T1 (enExample)
DK (1) DK2966079T3 (enExample)
ES (1) ES2572105T3 (enExample)
RU (1) RU2662713C2 (enExample)
WO (1) WO2014135028A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024532733A (ja) * 2021-08-10 2024-09-10 アムジエン・インコーポレーテツド 複素環式化合物及び使用方法
JP2024532734A (ja) * 2021-08-10 2024-09-10 アムジエン・インコーポレーテツド 複素環式化合物及び使用方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103588792B (zh) * 2013-03-04 2016-03-23 中国科学院上海药物研究所 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途
CN106008559B (zh) * 2015-03-25 2020-10-16 中国科学院上海药物研究所 取代吡啶并嘧啶类化合物的合成工艺
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2019091400A1 (zh) * 2017-11-07 2019-05-16 中国科学院上海药物研究所 吡啶并嘧啶类化合物的盐型和晶型及其制备方法
CN109867667B (zh) * 2017-12-05 2021-06-11 中国药科大学 含有吡啶并嘧啶结构的parp和pi3k双靶点抑制剂
CN113825760B (zh) * 2019-05-06 2022-08-19 南京明德新药研发有限公司 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法
WO2021247859A1 (en) * 2020-06-03 2021-12-09 Yumanity Therapeutics, Inc. Pyridopyrimidines and methods of their use
WO2022061251A1 (en) * 2020-09-18 2022-03-24 Plexxikon Inc. Compounds and methods for kras modulation and indications therefor
CN115260158A (zh) * 2021-04-30 2022-11-01 上海医药集团股份有限公司 一种靶向蛋白调节剂的化合物及其应用
JP2024532735A (ja) * 2021-08-10 2024-09-10 アムジエン・インコーポレーテツド 複素環式化合物及び使用方法
JP2025519743A (ja) * 2022-06-15 2025-06-26 ミラティ セラピューティクス， インコーポレイテッド 汎ＫＲａｓ阻害剤のプロドラッグ
WO2024057013A1 (en) * 2022-09-12 2024-03-21 Exscientia Ai Limited Nlrp3 modulators
CN117586255A (zh) * 2023-09-25 2024-02-23 上海图芃生物科技有限公司 一种口服atp竞争性激酶抑制剂及其合成方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010522209A (ja) * 2007-03-21 2010-07-01 ワイス エルエルシー ＰＩ３キナーゼおよびｍＴＯＲの阻害剤としてのイミダゾロピリミジン類似体およびその使用
WO2010120987A1 (en) * 2009-04-17 2010-10-21 Wyeth Llc Ring fused, ureidoaryl- and carbamoylaryl-bridged morpholino-pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
CN102887895A (zh) * 2011-07-22 2013-01-23 山东轩竹医药科技有限公司 吡啶并嘧啶类mTOR抑制剂
WO2013016999A1 (zh) * 2011-08-04 2013-02-07 江苏豪森药业股份有限公司 杂芳基并嘧啶类衍生物、其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007010401A (es) * 2005-02-25 2008-02-19 Kudos Pharm Ltd Derivados de 2,4-diamino-piridopirimidina y su uso como inhbidores de mtor.
UA96745C2 (en) * 2005-11-22 2011-12-12 Кудос Фармасьютикалз Лимитед PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
AU2007282535B9 (en) * 2006-08-08 2013-06-20 Chugai Seiyaku Kabushiki Kaisha Pyrimidine derivative as PI3K inhibitor and use thereof
CN101558067B (zh) * 2006-08-23 2014-05-28 库多斯药物有限公司 作为mtor抑制剂的2-甲基吗啉吡啶并、吡唑并和嘧啶并-嘧啶衍生物
CN103588792B (zh) * 2013-03-04 2016-03-23 中国科学院上海药物研究所 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010522209A (ja) * 2007-03-21 2010-07-01 ワイス エルエルシー ＰＩ３キナーゼおよびｍＴＯＲの阻害剤としてのイミダゾロピリミジン類似体およびその使用
WO2010120987A1 (en) * 2009-04-17 2010-10-21 Wyeth Llc Ring fused, ureidoaryl- and carbamoylaryl-bridged morpholino-pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
CN102887895A (zh) * 2011-07-22 2013-01-23 山东轩竹医药科技有限公司 吡啶并嘧啶类mTOR抑制剂
WO2013016999A1 (zh) * 2011-08-04 2013-02-07 江苏豪森药业股份有限公司 杂芳基并嘧啶类衍生物、其制备方法和用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PIKE, KURT G. ET AL.: "Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 23, no. 5, JPN6017029559, 2013, pages 1212 - 1216, ISSN: 0003938913 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024532733A (ja) * 2021-08-10 2024-09-10 アムジエン・インコーポレーテツド 複素環式化合物及び使用方法
JP2024532734A (ja) * 2021-08-10 2024-09-10 アムジエン・インコーポレーテツド 複素環式化合物及び使用方法

Also Published As

Publication number Publication date
US20150368274A1 (en) 2015-12-24
DK2966079T1 (da) 2016-05-17
EP2966079A1 (en) 2016-01-13
EP2966079B1 (en) 2021-11-24
CA2903072C (en) 2019-05-07
CN103588792B (zh) 2016-03-23
RU2662713C2 (ru) 2018-07-27
HK1217197A1 (en) 2016-12-30
RU2015140387A (ru) 2017-03-30
AU2014225155B2 (en) 2017-11-23
DK2966079T3 (da) 2022-02-14
CA2903072A1 (en) 2014-09-12
AU2014225155A1 (en) 2015-10-15
ES2572105T3 (es) 2022-04-13
ES2572105T1 (es) 2016-05-30
WO2014135028A1 (zh) 2014-09-12
DE14760712T1 (de) 2017-12-14
US9796732B2 (en) 2017-10-24
CN103588792A (zh) 2014-02-19
EP2966079A4 (en) 2016-11-09

Similar Documents

Publication Publication Date Title
AU2014225155B2 (en) Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition and use thereof
CN114981268B (zh) 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用
RU2742485C2 (ru) Гетероциклическое соединение, используемое как ингибитор fgfr
JP5350277B2 (ja) Ｐｉ３ｋ阻害剤としてのピロロピリミジン誘導体及びその用途
JP6248123B2 (ja) 塩誘導性キナーゼ２（ＳＩＫ２）阻害剤としての置換された１Ｈ−ピロロ［２，３−ｂ］ピリジン及び１Ｈ−ピラゾロ［３，４−ｂ］ピリジン誘導体
KR20250070059A (ko) 신규한 테트라헤테로사이클 화합물
CA3177261A1 (en) Benzothiazolyl biaryl compound, and preparation method and use
JP2022517723A (ja) Ｃｄｋ阻害剤としての大環状化合物、その製造方法及びその医薬品における応用
AU2019316858B2 (en) Smad3 inhibitors
JP5583698B2 (ja) プロテインキナーゼａｂｌおよびｓｒｃの阻害剤としてのアザインドール誘導体
AU2021300495B2 (en) Aryl phosphorus oxide compounds and use thereof
JP2022523477A (ja) ピロロピリミジン誘導体及びこれを有効成分として含有するタンパク質キナーゼ関連疾患の予防又は治療用薬学的組成物
CN115677730B (zh) 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途
JP2022502438A (ja) Ｆｇｆｒ４阻害剤及びその使用
WO2023003973A1 (en) Inhibitors targeting ubiquitin specific protease 7 (usp7)
TWI875911B (zh) Ｂｒｕｔｏｎ酪胺酸激酶（ＢＴＫ）抑制劑
KR101236731B1 (ko) 아자인돌 화합물, 이를 포함하는 ｐｉ３ｋ 저해제용 약학 조성물 및 ｐｉ３ｋ와 연관된 질환 치료용 약학 조성물
JP2025504495A (ja) Ｒａｓシグナル伝達の調節因子としての縮合複素環式化合物
JP2022528437A (ja) ピペラジンアミド誘導体、その製造方法及び医薬におけるその用途
HK1217197B (en) Pyridopyrimidine or pyrimidopyrimidine compound, preparation method, pharmaceutical composition and use thereof
HK40064179A (en) Piperazine amide derivative, preparation method therefor, and use thereof in medicine
HK1146937A (en) Pyrrolopyrimidin derivative for use as pi3k inhibitor, and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160809

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160809

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181001

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181212